Astellas Sees Turnaround With Urology, Transplantation And Oncology Products

Astellas has rolled out a five-year management plan to bounce back from patent expiries and declining sales; and fresh off a long-fought bid for OSI Pharmaceuticals, the company expects oncology to bolster growth driven by its core therapeutic competencies of urology and transplantation